Abstract
BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations. Nevertheless, several patients co-expressing the JAK2V617F mutation and the BCR-ABL1 transcript have been described in the literature. We report the case of a 61-year-old male who presented with an essential thrombocythaemia phenotype and had a subsequent diagnosis of chronic phase chronic myeloid leukaemia. Colony-forming assays demonstrated the coexistence of 2 different haematopoietic clones: one was positive for the JAK2V617F mutation and the other co-expressed both JAK2V617F and the BCR-ABL1 fusion gene. No colonies displayed the BCR-ABL1 transcript alone. These findings indicate that the JAK2V617F mutation was the founding genetic alteration of the disease, followed by the acquisition of the BCR-ABL1 chimeric oncogene. Our data support the hypothesis that a heterozygous JAK2V617F clone may have favoured the bi-clonal nature of this myeloproliferative disorder, generating clones harbouring a second transforming genetic event.
References
1.
Barbui
T
, Thiele
J
, Gisslinger
H
, Kvasnicka
HM
, Vannucchi
AM
, Guglielmelli
P
, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
. Blood Cancer J
. 2018
Feb
;8
(2
):15
.
[PubMed]
2044-53852.
Vainchenker
W
, Kralovics
R
. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
. Blood
. 2017
Feb
;129
(6
):667
–79
.
[PubMed]
0006-49713.
Stagno
F
, Vigneri
P
, Del Fabro
V
, Stella
S
, Cupri
A
, Massimino
M
, et al. Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
. Acta Oncol
. 2010
May
;49
(4
):506
–8
.
[PubMed]
0284-186X4.
Giallongo
C
, Parrinello
N
, Tibullo
D
, La Cava
P
, Romano
A
, Chiarenza
A
, et al. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients
. PLoS One
. 2014
Jul
;9
(7
):e101848
.
[PubMed]
1932-62035.
Massimino
M
, Consoli
ML
, Mesuraca
M
, Stagno
F
, Tirrò
E
, Stella
S
, et al. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation
. Carcinogenesis
. 2014
May
;35
(5
):1132
–43
.
[PubMed]
0143-33346.
Preyer
M
, Vigneri
P
, Wang
JY
. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL
. PLoS One
. 2011
Feb
;6
(2
):e17020
.
[PubMed]
1932-62037.
Giallongo
C
, Tibullo
D
, La Cava
P
, Branca
A
, Parrinello
N
, Spina
P
, et al. BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint
. Acta Haematol
. 2011
;126
(4
):205
–10
.
[PubMed]
0001-57928.
Manzella
L
, Tirrò
E
, Pennisi
MS
, Massimino
M
, Stella
S
, Romano
C
, et al. Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
. Curr Cancer Drug Targets
. 2016
;16
(7
):594
–605
.
[PubMed]
1568-00969.
Castagnetti
F
, Gugliotta
G
, Baccarani
M
, Breccia
M
, Specchia
G
, Levato
L
, et al.; GIMEMA CML Working Party
. Differences among young adults, adults and elderly chronic myeloid leukemia patients
. Ann Oncol
. 2015
Jan
;26
(1
):185
–92
.
[PubMed]
0923-753410.
Soderquist
CR
, Ewalt
MD
, Czuchlewski
DR
, Geyer
JT
, Rogers
HJ
, Hsi
ED
, et al. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group
. Mod Pathol
. 2018
May
;31
(5
):690
–704
.
[PubMed]
0893-395211.
Yamada
O
, Mahfoudhi
E
, Plo
I
, Ozaki
K
, Nakatake
M
, Akiyama
M
, et al. Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone
. J Clin Oncol
. 2014
Jul
;32
(21
):e76
–9
.
[PubMed]
0732-183X12.
Vigneri
P
, Stagno
F
, Stella
S
, Cupri
A
, Forte
S
, Massimino
M
, et al. High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
. Clin Cancer Res
. 2017
Dec
;23
(23
):7189
–98
.
[PubMed]
1078-043213.
Weng
WH
, Shih
LY
. Occurrence of BCR-ABL1-positive chronic myeloid leukemia following essential thrombocythemia
. Acta Haematol
. 2011
;126
(4
):220
–3
.
[PubMed]
0001-579214.
Wang
X
, Tripodi
J
, Kremyanskaya
M
, Blouin
A
, Roda
P
, Hoffman
R
, et al. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia
. Blood
. 2013
Feb
;121
(7
):1238
–9
.
[PubMed]
0006-497115.
Cambier
N
, Renneville
A
, Cazaentre
T
, Soenen
V
, Cossement
C
, Giraudier
S
, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders
. Leukemia
. 2008
Jul
;22
(7
):1454
–5
.
[PubMed]
0887-692416.
Inokuchi
K
, Yamaguchi
H
, Tamai
H
, Dan
K
. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia
. J Clin Exp Hematop
. 2012
;52
(2
):145
–7
.
[PubMed]
1346-428017.
Massimino
M
, Stella
S
, Tirrò
E
, Romano
C
, Pennisi
MS
, Puma
A
, et al. Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
. Mol Cancer
. 2018
Feb
;17
(1
):56
.
[PubMed]
1476-459818.
Stagno
F
, Vigneri
P
, Stagno
F
, Vigneri
P
, Del Fabro
V
, Stella
S
, et al. Uncommon long-term survival in a patient with chronic myeloid leukemia
. Acta Oncol
. 2009
;48
(8
):1215
–6
.
[PubMed]
0284-186X19.
Gambacorti-Passerini
C
, Antolini
L
, Mahon
FX
, Guilhot
F
, Deininger
M
, Fava
C
, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
. J Natl Cancer Inst
. 2011
Apr
;103
(7
):553
–61
.
[PubMed]
0027-887420.
Stagno
F
, Stella
S
, Spitaleri
A
, Pennisi
MS
, Di Raimondo
F
, Vigneri
P
. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
. Expert Rev Anticancer Ther
. 2016
;16
(3
):273
–8
.
[PubMed]
1473-714021.
Stagno
F
, Vigneri
P
, Del Fabro
V
, Stella
S
, Restuccia
N
, Giallongo
C
, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias
. Acta Oncol
. 2010
;49
(1
):109
–10
.
[PubMed]
0284-186X22.
Scott
LM
, Rebel
VI
. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?
Am J Hematol
. 2012
Nov
;87
(11
):1028
–36
.
[PubMed]
0361-860923.
Rumi
E
, Cazzola
M
. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms
. Br J Haematol
. 2017
Sep
;178
(5
):689
–98
.
[PubMed]
0007-1048© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
